Reslizumab, an anti-interleukin 5 monoclonal antibody, is found to be an effective therapy for patients with severe eosinophilic uncontrolled asthma (SEUA) and a history of severe exacerbations. A new study conducted by a team of scientists spanning various hospitals in Spain found that treatment with reslizumab achieved complete asthma control in 40 percent of the 208 SEUA patients included in the study and led to a significant reduction in exacerbations. The multi-centre, retrospective, real-life study reportedly analysed asthma patients from 44 asthma units across the country for 52 weeks. The researchers expressed that their work could help patients and clinical practitioners in future.